Galleri Test Accuracy: How Reliable Is the Multi‑Cancer Blood Test?

When assessing cancer detection tests like Galleri, two performance measures are critical:

• Sensitivity refers to the test's ability to correctly identify people who have cancer (true positives).^[2]
• Specificity refers to the ability to correctly identify those who do not have cancer (true negatives).^[2]

Together, these measures help determine how often a test gives false positives (detecting cancer when it's not present) or false negatives (failing to detect cancer that is present).^[2]

Galleri's performance data comes from an ongoing clinical evidence program that now includes more than 380,000 participants across completed and ongoing studies, including the large-scale PATHFINDER 2 interventional trial—the largest MCED study conducted to date in the US.^[11,12]

One of Galleri's strengths is its high specificity, currently reported at 99.6%.^[11,12] In practical terms, that means the test rarely tells a healthy person they might have cancer when they don't—Galleri's false-positive rate works out to roughly 1 in 250 people tested.^[11]

Why this matters: a false positive doesn't just cause worry. It can trigger unnecessary follow-up scans, biopsies, or procedures—each with its own cost, risk, and anxiety. Galleri's low false-positive rate helps minimize how often that happens to people who are, in fact, cancer-free.

While Galleri is highly specific, its sensitivity varies based on cancer type and stage. According to the Circulating Cell-free Genome Atlas (CCGA) study, Galleri achieved an overall sensitivity of 51.5%, meaning it correctly identified cancer in approximately half of the individuals who had it.^[4]

However, detection rates are stage-dependent, increasing dramatically for later-stage cancers:^[4]

• Stage I: 16.8% (14.5–19.5%)
• Stage II: 40.4% (36.8–44.1%)
• Stage III: 77.0% (73.4–80.3%)
• Stage IV: 90.1% (87.5–92.2%)

This means Galleri is most effective for detecting cancers in stages III and IV, where tumor DNA is more abundant in the bloodstream, but less reliable for early-stage detection.

That said, sensitivity looks meaningfully better when narrowed to the cancers that matter most clinically. For 12 cancer types responsible for roughly two-thirds of all U.S. cancer deaths—including lung, pancreatic, and liver cancer—Galleri's sensitivity across all stages rises to 76.3%.^[12,13]

Two major clinical trials, PATHFINDER-1 and PATHFINDER-2, have evaluated Galleri's real-world performance. These studies focused on how well the test performs in average-risk adults and how its results are used in clinical workflows.

PATHFINDER-1 Highlights^[3]

• Enrolled 6,621 individuals aged 50+
• Cancer signal was detected in 1.4% of participants
• Of those with a detected signal, 43% were confirmed to have cancer after diagnostic evaluation
• Specificity remained at 99.5%
• The test correctly identified the Cancer Signal Origin (CSO) in 88% of cases

PATHFINDER-2 Results^[11,12]

PATHFINDER 2 is the largest interventional MCED study conducted in the US to date, and its results show measurable improvement over PATHFINDER-1:

• Specificity improved to 99.6%, with a false-positive rate of approximately 1 in 250 people tested
• Positive predictive value (PPV) of 61.6%—meaning about 6 in 10 people with a "Cancer Signal Detected" result are ultimately diagnosed with cancer
• Cancer Signal Origin accuracy improved to 93.4%
• Among the first ~25,000 participants followed for one year, adding Galleri to standard USPSTF-recommended screenings (breast, cervical, colorectal, and lung) resulted in 3 times as many cancers detected compared to standard screening alone

These results suggest that Galleri can detect cancer with a high degree of accuracy, particularly when used in conjunction with other clinical tools.

When Galleri detects a cancer signal, it also predicts where in the body the cancer likely originated, known as the Cancer Signal Origin (CSO). The accuracy of this prediction is crucial for directing follow-up diagnostic tests.

In clinical studies, Galleri's CSO accuracy has ranged from 88% to 97%, depending on the study population and cancer type.^[3,6] In the more recent PATHFINDER 2 study, CSO accuracy reached 93.4% among participants ultimately diagnosed with cancer.^[11,12] This high level of precision enables physicians to focus imaging and biopsies efficiently.

Unlike traditional screening tests that target specific cancers (such as mammograms or colonoscopies), Galleri is designed to detect a wide range of cancers, including those without routine screening protocols such as pancreatic, ovarian, and esophageal cancers.^[7]

Compared to other MCED tests, Galleri shows superior performance:

• Positive predictive value (PPV) of 61.6%, compared to ~28.3% in the DETECT-A study^[8,11]
• Validated across a clinical evidence program of more than 380,000 participants^[11,12]

However, no MCED test—including Galleri—should replace routine screenings for cancers with established guidelines.

Strengths

• Very low false-positive rate (0.4%)^[11,12]
• High CSO accuracy (up to 93.4% in PATHFINDER 2)^[11,12]
• Detects over 50 cancer types, including those without standard screening tools^[3]
• Useful for adults aged 50+ with no symptoms but elevated risk^[3]

Limitations

• Lower sensitivity for early-stage cancers, especially Stage I (~17%)^[3]
• False negatives possible—absence of a signal ≠ absence of disease
• Not FDA-approved as a standalone screening tool and not covered by insurance^[9]
• Cost may be prohibitive (~$949 without insurance)^[10]

One concern with novel screening methods is the potential psychological burden of false positives. In the PATHFINDER study, most participants reported minimal distress and high satisfaction with the testing process.^[3]

Diagnostic resolution time—how long it takes to confirm or rule out cancer after a positive Galleri result—was typically within three months.^[3]

The Galleri test represents a major step forward in cancer screening, particularly for hard-to-detect cancers. Its exceptionally high specificity and CSO accuracy reduce false alarms and streamline care. However, lower sensitivity in early stages and lack of FDA approval mean it should complement—not replace—routine screenings.

For adults aged 50 and older or those at elevated risk, Galleri may be a valuable proactive health tool. As with any medical test, it’s important to understand its strengths and limitations before deciding whether it’s right for you.

Ready to explore Galleri for yourself? Order the Galleri Cancer Screening Test from Everlywell and take the next step in proactive, personalized cancer detection.